Table 3.
Summary of AEs reported by at least 5 % of the subjects after any treatment, n = 24
| PBOa n (%) | S15 n (%) | S30 n (%) | ZOP n (%) | |
|---|---|---|---|---|
| Subjects with at least 1 AE | 13 (54.2) | 14 (58.3) | 13 (54.2) | 11 (45.8) |
| Headache | 7 (29.2) | 2 (8.3) | 5 (20.8) | 3 (12.5) |
| Somnolence | 4 (16.7) | 2 (8.3) | 7 (29.2) | 3 (12.5) |
| Dysgeusia | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (12.5) |
| Fatigue | 0 (0.0) | 2 (8.3) | 1 (4.2) | 1 (4.2) |
| Dizziness | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (8.3) |
| Poor sleep quality | 3 (12.5) | 6 (25.0) | 0 (0.0) | 0 (0.0) |
| Nightmare | 3 (12.5) | 1 (4.2) | 2 (8.3) | 1 (4.2) |
aIncludes placebo treatment days 2 to 7 in ZOP. PBO, placebo; S15, suvorexant 15 mg; S30, suvorexant 30 mg; ZOP, zopiclone 7.5 mg